Paragraph IV ANDA Expert Support
Scientific work plans, comparative testing, and expert-science support for ANDA and Hatch-Waxman technical issues.
Evaluate whether solid-state claims are supported, reproducible, and defensible
Solid-state patent strength depends on more than naming a form. The evidence must show what the material is, how it is distinguished, how reproducibly it can be made or detected, what analytical limits apply, and whether competing explanations have been reasonably addressed.
Triclinic evaluates solid-state evidence for polymorphs, salts, cocrystals, hydrates, solvates, amorphous materials, formulations, mixtures, and process-induced changes. The assessment is scientific, not legal: it identifies technical strengths, gaps, uncertainties, and experiments that may strengthen or test the position.
This work can support prosecution strategy, portfolio assessment, lifecycle planning, ANDA preparation, litigation support, or technical diligence.
When this page is the right starting point
- A patent application, issued patent, or proposed claim depends on a solid form, formulation, analytical signature, or material property.
- A team needs to know whether the claimed form can be made, identified, distinguished, and reproduced.
- The available data may not separate polymorphism, hydration, solvation, crystallinity, excipient interference, morphology, or processing effects.
- Counsel or technical teams need a gap assessment before prosecution, litigation, diligence, or partnering decisions.
- Additional experiments may be needed to test or strengthen the technical position.
How Triclinic approaches solid-state patent strength assessment
Triclinic maps the claim or technical position to measurable solid-state evidence. The assessment considers whether analytical methods are specific to the claimed material, whether the data distinguish relevant alternatives, and whether the result can be reproduced under practical conditions.
The work may combine document review, data review, experimental design, comparative testing, prior-art reproduction, and orthogonal analytical characterization. The goal is to identify what the data actually support and where additional evidence would materially improve the position.
The assessment stays focused on technical support. Legal conclusions about patentability, validity, infringement, or freedom to operate remain with counsel.
- Map claim elements or technical assertions to measurable material attributes.
- Evaluate the strength and specificity of analytical data such as XRPD, Raman, FTIR, NMR, DSC, TGA, DVS, microscopy, chromatography, SCXRD, or MicroED.
- Assess whether methods distinguish relevant polymorphs, salts, cocrystals, hydrates, solvates, amorphous phases, mixtures, or formulation effects.
- Review reproducibility, sample history, material handling, and processing conditions.
- Recommend experiments that can close technical gaps or test vulnerable assumptions.
Solid-state evidence that often matters
Solid-state claims can be vulnerable when evidence is narrow, non-specific, unreproduced, or insensitive to mixtures and conversions. A technically useful assessment identifies whether the data distinguish the claimed material from plausible alternatives and whether the method is fit for the intended comparison.
The strongest packages often combine structural, thermal, spectroscopic, microscopic, moisture, chromatographic, and process-context evidence.
- Form identification and differentiation for polymorphs, salts, cocrystals, hydrates, solvates, and amorphous materials.
- Reproducibility of preparation, isolation, drying, storage, and analytical preparation.
- Phase purity, mixtures, conversion, and detection-limit questions.
- Excipient interference and formulation-matrix effects.
- Alignment between claim language, examples, analytical data, and technical conclusions.
Lifecycle-management relevance of solid-state claims
DrugPatentWatch identifies secondary patent strategies, including polymorph, formulation, method-of-use, and manufacturing-process claims, as part of pharmaceutical lifecycle planning when primary composition claims mature or commercial exclusivity is under pressure. Solid-state claims only have practical value if the asserted form or property can be made, distinguished, measured, and explained under conditions that survive technical scrutiny.
Triclinic evaluates the scientific record behind that position: whether the claimed form is analytically distinguishable, whether alternative forms or mixtures could explain the data, whether examples are reproducible, and whether additional characterization would strengthen or weaken the technical evidence.
Review DrugPatentWatch’s overview of pharmaceutical patent longevity
Typical deliverables
- Claim or technical-position evidence matrix.
- Review of available analytical data and method specificity.
- Gap assessment for missing, weak, ambiguous, or non-specific evidence.
- Experimental plan for strengthening or testing the technical position.
- Comparative characterization data where new testing is performed.
- Technical memorandum or report for counsel, scientists, or experts.
Related services and capabilities
Reproduction of Prior Art
Controlled execution and characterization of prior-art examples where the resulting material matters.
Testifying and Fact Experts
Fact and expert-science support for chemistry, materials, and solid-state disputes.
Solid Form Development
Screening, selection, characterization, and control of polymorphs, salts, cocrystals, hydrates, solvates, and amorphous materials.
Structure Elucidation
Crystal, molecular, impurity, and structure-determination support when structural proof is central to the question.
Common questions
Common questionsWhat makes a solid-state patent position technically stronger?
Strong support usually requires reproducible preparation or detection, specific analytical differentiation, clear sample history, appropriate controls, and a data package that addresses plausible alternative forms or explanations.
Can Triclinic assess patents before litigation?
Yes. Triclinic can review data and design experiments before prosecution, litigation, diligence, partnering, or portfolio decisions. The work is technical support, not legal advice.
Can the assessment include new experiments?
Yes. The work can include data review only, experimental testing only, or both. New experiments are useful when available data do not answer the technical question.
Which solid forms can be evaluated?
Polymorphs, salts, cocrystals, hydrates, solvates, amorphous materials, mixtures, formulations, and process-induced forms can be evaluated when appropriate samples and project scope are available.
Does Triclinic guarantee patent strength?
No. Triclinic identifies technical strengths, gaps, and risks in the scientific evidence. Patent strength and legal strategy remain legal questions for counsel.
What evidence commonly weakens a solid-state patent position?
Common weaknesses include irreproducible preparation, ambiguous form assignment, inadequate controls, inconsistent sample history, unsupported quantitation, failure to address mixtures or alternative forms, and claims broader than the experimental evidence.
Review patent strength
Share the patent, claim language, examples, available analytical data, material history, samples, and the decision point. Triclinic can help determine whether the evidence supports the solid-state position or whether additional experiments are needed.
